As per attachment

Pat Growth 25pctExceptional ItemEbitda Margin ExpansionResults View source PDF

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹2446.00

prior close

₹2419.30

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.6-0.5-0.5—-1.3-0.3-2.3-2.4-4.0-5.4-11.4-13.5-1.0—

Up moveDown movePending

AI summary

GlaxoSmithKline Pharmaceuticals reported FY26 consolidated revenue of Rs. 382,167 lakhs, up 1.9% from Rs. 374,921 lakhs in FY25. Profit after tax grew 11.7% to Rs. 103,598 lakhs from Rs. 92,758 lakhs. EPS increased to Rs. 61.15 from Rs. 54.76. The Board recommended a final dividend of Rs. 57 per share (up from Rs. 54 total dividend in FY25), with record date 29th May 2026 and payment after 1st July 2026. Exceptional items of Rs. 2,062 lakhs came from property sales. Auditors Deloitte issued an unmodified clean opinion. New labour codes added Rs. 1,182 lakhs to employee costs.

Likely market impact

The company delivered solid profit growth with an improved dividend, indicating strong cash generation. Clean audit opinion and positive operating cashflow of Rs. 90,330 lakhs are positive signals for shareholders.